Core Viewpoint - Lepu Medical claims to possess global intellectual property rights for MWN109 injection and oral tablets, despite existing patents from major companies like Eli Lilly and Novo Nordisk related to molecular structure and delivery technology [1] Group 1 - Lepu Medical has independently developed MWN109 and holds global intellectual property rights for the drug [1] - The company has applied for patent protection on key aspects of the core compound structure [1] - Lepu Medical has conducted a Freedom to Operate (FTO) due diligence investigation regarding potential patent overlaps [1]